Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The ...
Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...
Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...
Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback